Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.58 |
| ▸ | PDE4A | P27815 | 3/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9645577 | 0.91 | ADORA2A (0.55) | ADORA2AADORA2BADORA1PDE4APDE4B | |
| SCHEMBL9645161 | 0.90 | ADORA2A (0.54) | ADORA2AADORA2BADORA1PDE4APDE4B | |
| SCHEMBL4623457 | 0.89 | ADORA2A (0.59) | ADORA2AADORA2BADORA1PDE4APDE4B | |
| SCHEMBL11017311 | 0.89 | ADORA2A (0.51) | ADORA2AADORA2BADORA1PDE4APDE4B | |
| SCHEMBL3990423 | 0.89 | ADORA1 (0.54) | ADORA2AADORA2BADORA1PDE4APDE4B | |
| SCHEMBL3848060 | 0.85 | ADORA2A (0.57) | ADORA2AADORA2BADORA1PDE4APDE4B | |
| SCHEMBL11015546 | 0.84 | ADORA2A (0.54) | ADORA2AADORA2BADORA1PDE4APDE4B | |
| SCHEMBL9645114 | 0.81 | ADORA2A (0.49) | ADORA2AADORA2BADORA1PDE4APDE4B | |
| SCHEMBL4626790 | 0.81 | ADORA2A (0.58) | ADORA2AADORA2BADORA1PDE4APDE4B | |
| SCHEMBL3180528 | 0.80 | ADORA2A (0.59) | ADORA2AADORA2BADORA1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009118759-A2 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD., (IN) | 2009-10-01 | — | — | WO | claimed |
| US-20040106797-A1 | Novel xanthines having adenosine A1-receptor antagonist properties | ARYX THERAPEUTICS | 2004-06-03 | — | — | US | claimed |
| WO-2004009594-A2 | XANTHINE DERIVATIVES HAVING ADENOSINE A1-RECEPTOR ANTAGONIST PROPERTIES | ARYX THERAPEUTICS (US) | 2004-01-29 | — | — | WO | claimed |
| WO-1999031101-A1 | ADENOSINE RECEPTOR ANTAGONISTS WITH IMPROVED BIOACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 1999-06-24 | — | — | WO | claimed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-02-03 | — | — | US | disclosed |
| US-11208475-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210283217-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11059886-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210177823-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-17 | — | — | US | disclosed |
| US-11034751-B1 | Methods and compositions for treating cancer using serotonin receptor inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-1092435-A1 | REMEDIES FOR DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-18 | — | — | EP | disclosed |
| EP-1051192-A2 | METHODS FOR THE PREVENTION AND TREATMENT OF FIBROSIS AND SCLEROSIS | Link Technology, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999038532-A2 | METHODS FOR THE PREVENTION AND TREATMENT OF FIBROSIS AND SCLEROSIS | LINK TECHNOLOGY, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1999031101-A1 | ADENOSINE RECEPTOR ANTAGONISTS WITH IMPROVED BIOACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0619316-B1 | Xanthine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1998-08-12 | — | — | EP | disclosed |
| EP-0619316-A1 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993021949-A1 | IMMUNOLOGICAL DETECTION AND QUANTIFICATION OF 8-(CYCLOALKYL OR AROMATIC) SUBSTITUTED-1,3-DIPROPYLXANTHINES | VANDERBILT UNIVERSITY (US) | 1993-11-11 | — | — | WO | disclosed |
| US-4546182-A | TREATMENT OF RESPIRATORY AND CARDIO-VASCULAR DISORDERS | AKTIEBOLAGET DRACO (SE) | 1985-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | CHRNA6, CHRNA1, CHRNB1 | ADORA2A 90/4885ADORA2B 76/4885ADORA1 34/4885 |
| US-20040106797-A1 | Novel xanthines having adenosine A1-receptor antagonist properties | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 4/4885ADORA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.